Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
31658127
Public Release Type:
Journal
Publication Year: 2019
Affiliation: Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California, USA.; Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; California Pacific Medical Center, San Francisco, California, USA.; Saint Louis University, St. Louis, Missouri, USA.; Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.; Liver Diseases Branch, National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.; Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California, USA.; Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.; Hepatology Division, Baylor University Medical Center, Dallas, Texas, USA.; Division of Digestive and Liver Diseases, UT Southwestern Medical Center at Dallas, Dallas, Texas, USA.; Liver Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.; Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, Virginia, USA.; University Health Network, Toronto General Hospital, Toronto, Ontario, Canada.; Division of GI and Liver Diseases, University of Southern California, Los Angeles, California, USA.
DOI:
https://doi.org/10.14309/ajg.0000000000000400
Authors:
Zhou Kali, Wahed Abdus S., Cooper Stewart, Di Bisceglie Adrian M., Fontana Robert J., Ghany Marc G., Khalili Mandana, Lok Anna S., Perrillo Robert, Lee William, Lau Daryl, Sterling Richard, Janssen Harry L.A., Terrault Norah A.
Request IDs:
20876
,
21197
Studies:
Hepatitis B Research Network Adult Cohort Study
Patients with hepatitis B e-antigen (HBeAg)-negative chronic hepatitis B (CHB) and low-level viremia are a heterogeneous group. Identifying those at risk of developing active CHB requiring antiviral therapy is important. In this study, we prospectively characterize incidence rates and predictors of transitioning from inactive to active CHB in a North American adult cohort.
